An accumulating body of evidence is consistent with the concept that the onset and progression of Alzheimer's disease (AD) is influenced by lifestyle factors including nutrition(Reference Pasinetti and Eberstein1). Several population studies have found that SFA are a positive risk factor for AD(Reference Kalmijn2–Reference Petot and Friedland3) and in animal models of AD, SFA or cholesterol feeding markedly exacerbates cerebral pathology(Reference Sparks, Scheff and Hunsaker4–Reference Refolo, Malester and LaFrancois5). However, the mechanisms that link dietary fat to the pathogenesis of AD are unclear.
The cerebrovasculature in subjects with AD shows pathological alterations including vascular endothelial and smooth muscle cell proliferation(Reference Ellis, Olichney and Thal6). Blood plasma proteins have been detected in the parenchyma of AD brains(Reference Kalaria7–Reference Wisniewski, Vorbrodt and Wegiel8) and inflammatory sequalae are commonly reported(Reference Cullern9–Reference Itagaki, McGeer and Akiyama10), observations that are consistent with breakdown of the blood–brain barrier (BBB). Yet despite evidence supportive of AD having an underlying vascular component, most research focuses on damage of neurons(Reference Hachinski and Munoz11).
A major neuropathological marker of AD is amyloid-β (Aβ) deposition in the cerebrovasculature and in the cerebral parenchyma. Derived from amyloid precursor protein (APP), Aβ is the predominant component of amyloid plaque(Reference Joachim, Duffy and Morris12). The source of cerebral Aβ deposits in AD is uncertain, though there is little evidence for increased cerebral Aβ production in sporadic, late-onset AD which accounts for over 96 % of AD cases. Rather, decreased Aβ clearance across the BBB via receptor pathways and/or via the choroid plexus has been suggested as an initiating pathway for amyloidosis(Reference Deane, Sagare and Hamm13–Reference Crossgrove, Li and Zheng15). More recent has been evidence of blood-to-brain delivery of circulating Aβ, a process that would conceivably exacerbate parenchymal load in the absence of compensatory clearance pathways(Reference Donahue, Flaherty and Johanson16).
Plasma Aβ can be derived from vascular smooth muscle cells and endothelial cells, or from blood platelets. However, another significant source of plasma Aβ may be from lipogenic organs such as the small intestine and liver(Reference Galloway, Jian and Johnsen17–Reference Koudinov and Koudinova19). Hepatocytes and absorptive epithelial cells of the small intestine (enterocytes) secrete Aβ as a lipoprotein complex, and in the small intestine this pathway is under dietary regulation(Reference Galloway, Jian and Johnsen17–Reference James, Pal and Gennat20). Chronic ingestion of SFA was reported to significantly enhance enterocytic abundance of Aβ and conversely the protein could not be detected when animals were fasted(Reference Galloway, Jian and Johnsen17).
Distributional analysis of plasma lipoprotein–Aβ in normal subjects and those with AD or mild cognitive impairment (MCI) is consistent with the notion that dietary-induced Aβ may contribute to the aetiology of AD(Reference Mamo, Jian and James21). In control and in AD/MCI subjects, greater than 60 % of plasma lipoprotein–Aβ was found to be associated with TAG-rich lipoproteins (TRL); however, this was significantly increased in AD/MCI subjects v. controls. Moreover, whilst the AD subjects were normolipidaemic and had similar plasma levels of hepatically derived lipoproteins, the concentration of apo B48 (an exclusive marker of chylomicrons) was elevated more than three-fold in post-absorptive AD subjects. Increased apo B48 is indicative of postprandial dyslipidaemia, an exaggerated rise in plasma chylomicrons that occurs following the ingestion of dietary fats(Reference Smith, Watts and Dane-Stewart22). Consistent with the notion of an Aβ postprandial response, ingestion of a lipid-enriched meal was found to cause a transient increase in the plasma concentration of APP and of Aβ in otherwise healthy subjects(Reference Boyt, Taddei and Hallmayer23).
Evidence of a causal link between plasma lipoprotein–Aβ and AD also comes from studies in animal models of AD. In transgenic mice that over-express APP, plasma Aβ concentration correlated with secretion rates into the blood of TRL, which was increased 3- to 8-fold above wild-type controls(Reference LaRue, Hogg and Sagare24). Furthermore, there was a positive association between plasma TRL–Aβ secretion with onset of cerebrovascular and parenchymal amyloidosis(Reference Burgess, McIsaac and Naus25).
The mechanisms by which circulating Aβ increases AD risk are presently unclear. However, several studies have provided evidence of a vasoactive role of Aβ, with pathological manifestations before Aβ deposition(Reference Arendash, Su and Crawford26–Reference Thomas, McLendon and Sutton28). Aβ is vasoconstrictive and vessels treated with Aβ show significant endothelial cell damage, with changes in the cell membrane, cytoplasm, nucleus and other organelles.
We hypothesise that SFA may adversely influence BBB function, because of exaggerated exposure to plasma lipoprotein–Aβ that leads to greater rates of plasma to cerebral Aβ delivery. In previous studies, integrity of the BBB has been assessed in experimental colitis(Reference Natah, Mouihate and Pittman29) and following acute intravenous injection of solubilised, exogenous Aβ(Reference Arendash, Su and Crawford26–Reference Thomas, McLendon and Sutton28). Consistent with the notion that lipoproteins have an important role in central nervous system diseases, Kay et al. reported significant remodelling of cerebrospinal fluid lipoproteins after subarachnoid haemorrhage(Reference Kay, Day and Nicoll30). However, the potential effect of SFA on plasma Aβ homeostasis and BBB function have not been reported. If this hypothesis is correct, it may explain epidemiological data that link SFA intake with AD risk. In the present study we directly explore BBB integrity in wild-type mice fed fatty acid-enriched diets.
Materials and methods
Animals
Female C57BL/6J mice, aged 6 weeks, were purchased from the Animal Resource Centre (Perth, WA, Australia). Mice were randomly allocated to either the control or one of three fatty acid treatment groups (see Dietary intervention in wild-type mice section). Mice were maintained in an accredited animal holding facility with regulated temperature, air pressure and lighting (12 h light–12 h dark). Mice had ad libitum access to feed and water. At 3 and 6 months following commencement of the dietary intervention, six mice from each group were killed by cardiac exsanguination under complete anaesthesia. The C57BL6J mice were considered an appropriate wild-type strain because the transgenic APP/presenilin-1 (APP/PS1) mice are a C57BL6J × C3H strain.
Double transgenic APP/PS1 mice develop AD-like brain pathology after 20 weeks of age. In the present study APP/PS1 mice were fed a standard low-fat rodent chow and killed at 12 months of age.
All experimental procedures used in this project were approved by a National Health and Medical Research Council (Australia) accredited Animal Ethics Committee (Curtin University approval no. R34/08).
Dietary intervention in wild-type mice
The feed preparations were made by Glenn Forest Stock Feeders (Perth, WA, Australia). The low-fat control diet was a standard American Institute of Nutrition AIN-93M rodent chow containing < 4 % (w/w) fat as polyunsaturates, with < 1 % total digestible energy as lipids and was free of cholesterol (for details, see Table 1). All of the fat-enriched diets comprised 40 % total digestible energy as lipids (or 20·3 %, w/w). For the SFA intervention group, the principal fatty acid types were palmitic (16 : 0) and stearic (18 : 0) (13 %, w/w) but the SFA diet also contained some oleic acid (18 : 1n-9, 6 %, w/w). The MUFA diet contained approximately 16 % as oleic acids, approximately 1·5 % as SFA and only trace amounts of PUFA. The PUFA-enriched diet was principally made up of DHA (22 : 6n-3), EPA (20 : 5n-3) and oleic acid. SFA and MUFA accounted for less than 4 % (w/w) of the PUFA-enriched diet. The MUFA and PUFA diets reflected blends of Sunola™ oil and fish oils, respectively.
(Percentages)
n/a, Not applicable.
* Detailed dietary compositions of the diet of low-fat control, saturated fat (SFA), monounsaturated fat (MUFA) and polyunsaturated fat (PUFA) groups are given.
Tissue and plasma sample collection
Following dietary intervention for 3 or 6 months, mice were anaesthetised with pentobarbitone and blood samples obtained by cardiac puncture. Plasma was separated by low-speed centrifugation and stored immediately at − 80°C. Brains were carefully removed and washed in chilled PBS. For immunofluorescent microscopy, the right hemisphere was segmented and fixed in 4 % paraformaldehyde for 24 h followed by cryoprotection in 20 % sucrose solution for 3 d at 4°C. Tissues were then frozen in isopentane/dry ice and stored at − 80°C.
Plasma S100B and amyloid-β analysis
Plasma S100B was measured by ELISA (CosmoBio, Tokyo, Japan) according to the instructions provided by the manufacturer. Briefly, 20 μl of plasma samples, or of the S100B standards (0, 98, 197, 394, 1575, 3150 and 6300 pg/ml) were incubated overnight at 4°C in ninety-six-well microplates coated with the primary antibody. Thereafter, plates were incubated with the conjugated secondary antibody for 2 h, followed by 2 h incubation with streptavidin–horseradish peroxidase. Finally samples were incubated with substrate solution for 20 min and the reaction was terminated with stopping solution. The optical absorbance was measured at 490 nm.
Plasma concentrations of mouse Aβ1–40 and Aβ1–42 were measured utilising Biosource ELISA kits (KMB3441; Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Plasma (100 μl) or Aβ standards (Aβ1–40: 0, 7·8, 15·6, 31·3, 62·5, 125, 250, 500 pg/ml; Aβ1–42: 0, 3·12, 6·25, 12·5, 25, 50, 100, 200 pg/ml) were dispensed into wells and incubated for 2 h at room temperature, then thoroughly washed. The primary antibody for either Aβ1–40 or Aβ1–42 was then added and incubated for 1 h at room temperature. Anti-rabbit IgG–horseradish peroxidase was added for 30 min, then incubated with stabilised chromogen for an additional 30 min in darkness. The optical absorbance was measured at 450 nm.
Immunofluorescent detection of IgG, apo B, occludin and von Willebrand factor in cerebral tissue
Cryosection specimens of 18 μm were prepared from the right hemisphere of the brain of each mouse. For IgG detection, sections were incubated with polyclonal goat anti-mouse IgG antibody conjugated with Alexa 488 fluorochrome (1:100; Abcam, Inc., Cambridge, MA, USA) for 2 h at room temperature. Subsequently, the sections were imaged utilising an inverted fluorescent microscope (Zeiss AxioVert 200M; Carl Zeiss, Jena, Germany) and AxioVision software (version 4.6; Carl Zeiss).
Apo B lipoproteins were detected by overnight incubation with polyclonal rabbit anti-apo B antibody (1:200; Abcam, Inc.). The primary antibody was then visualised with goat-anti-rabbit IgG conjugated with Alexa 488 (Invitrogen).
Negative controls were included for all immunofluorescent experiments and included replacement of the primary antibody with buffer, or an irrelevant serum. Fluorescent staining was not observed for any negative control tissue preparations.
Fluorescent image capture and semi-quantitative measurement
All fluorescent images were captured with a fluorescent microscope (AxioVert 200M) coupled to an MRm digital camera and managed by AxioVision software (version 4.6; Carl Zeiss). Three-dimensional (3-D) images were taken with ApoTome optical sectioning methodology (Carl Zeiss). Quantification was determined within the cortex excluding the hippocampus (CTX), hippocampal formation (HPF) and brain stem (BS).
For each mouse killed, a minimum of three cryosection specimens was prepared from the right hemisphere of the brain. For each specimen, up to seven 3-D ApoTome images were randomly taken within each designated region of the brain. For IgG and apo B quantitative measurement, images were captured at × 200 magnification (430 × 322 μm). Each 3-D image consisted of six to thirteen Z-stack images and the distance between Z-stack slices was 1·225 μm optimised by Nyquist theory (2 × oversampling in axial direction). The optical densitometric sum for the protein of interest was determined in three dimensions (1388 × 1040 pixel two-dimensional planes) utilising the automated optical density measurement tool (AxioVision; Carl Zeiss).
Double immunofluorescent detection with two polyclonal antibodies
In order to detect two different proteins with two polyclonal antibodies raised in the same species, a double immunofluorolabelling method was used as we have previously described(Reference Takechi, Galloway and Pallebage-Gamarallage31). For the co-localisation of Aβ with perivascular leakage of plasma apo B, rabbit polyclonal anti-Aβ1–40/42 (Chemicon; Millipore, Billerica, MA, USA) and rabbit polyclonal anti-apo B antibodies were used. For the BBB tight junction protein occludin and the vascular endothelial cell marker von Willebrand factor (vWF), these were detected with rabbit polyclonal anti-occludin-1 (Invitrogen) and rabbit polyclonal anti-vWF antibodies (Abcam, Inc.). Briefly, 10 μm sections were fixed in acetone for 3 min at − 20°C and heat-mediated antigen retrieval was achieved by incubating in a water-bath at 60°C for 3 h. Endogenous biotin was blocked with avidin in egg white and biotin in skimmed milk. In order to avoid the cross-reaction of the two polyclonal antibodies, the concentration of the first antibody was diluted so that it was undetectable with conventional secondary antibody detection, but detectable after the signal amplification with the biotin–avidin reaction. Subsequently the second protein of interest was detected with standard secondary detection.
For the co-localisation analysis of Aβ and apo B in cerebral tissue of wild-type mice given different fatty acid-enriched diets, fifteen 3-D images were captured at × 400 magnification (222 × 166 μm). Each of the 3-D images contained thirty-two to seventy-one Z-stack images and the distance between Z-stack slices was 0·275 μm. From a total of 695 two-dimensional images, co-localisation of Aβ and apo B was then determined with AxioVision software and data were expressed as Manders' and Pearson's correlation coefficients. Manders' correlation coefficient estimates the co-localisation independent of fluorescent intensity, whereas Pearson's correlation coefficient explores if there is also an association in fluorescent intensities.
For vWF and occludin measurement, 3-D ApoTome images were taken at × 200 magnification. Each 3-D image consisted of a minimum of three and up to seven Z-stack images and distance between Z-stack slices was 1·225 μm. To measure the relative abundance of vWF, the optical densitometric sum within the image was determined and expressed as per vWF per volume of tissue. In order to measure occludin abundance specific for the cerebrovasculature, only occludin staining which co-localised with vWF was measured.
Co-localisation of apo B with cerebral amyloid plaques
To examine the co-localisation of apo B with amyloid plaques in 12-month-old APP/PS1 transgenic mice, the immunofluorescent double labelling method was used as described for the wild-type mice given fat-enriched diets. In the APP/PS1 mice, 50 μm thick cryosections were fixed with 4 % paraformaldehyde for 1 h and heat-mediated antigen retrieval was done by incubating the sections in 60°C water for 3 h. A mixture of rabbit-derived anti-apo B and mouse monoclonal anti-Aβ antibodies was applied and incubated for 3 d at 4°C. Following washing with PBS, the primary antibodies were detected with anti-rabbit IgG Alexa 488 and anti-mouse IgG1 Alexa 680, respectively. Immunofluorescent 3-D images were captured at × 400 magnification with ApoTome.
Statistical analysis
There were twelve mice in each dietary group studied. For the immunodetection of IgG, apo B, occludin and vWF, up to seven 3-D images were obtained for each of the three regions of the brain studied (CTX, HPF and BS). Each 3-D image was generated from a stack of two-dimensional images, consisting of between twenty-two and 181 sequential images. The 3-D stacks represented 4·9–18·5 μm tissue thickness. For co-localisation analysis of apo B with Aβ in SFA-fed mice and in APP/PS1 mice, three to six 3-D images were generated per animal, with ten mice in the SFA group and six mice in the APP/PS1 group. A total of 694 images were analysed in SFA-fed mice and 834 images in transgenic APP/PS1 mice. Data were normally distributed and compared by one-way ANOVA followed by Tukey's post hoc test or Student's t test using SPSS (SPSS, Inc., Chicago, IL, USA). Data were expressed as mean values with their standard errors.
Results
The fatty acid-supplemented diets given to mice were well tolerated. There was no difference in plasma lipids or body weight following 3 or 6 months of dietary intervention (data not shown).
IgG (150 kDa) immunoreactivity was used as a generic marker of blood-to-brain influx of plasma proteins. In mice fed the SFA diet for 3 months, we identified significant perivascular leakage of IgG into the CTX, BS and to a lesser extent, within the HPF (Figs. 1 and 2). At 6 months of feeding, IgG leakage was more evident than at 3 months (Figs. 1 and 2). In contrast, in the mice given the low-fat control diet, or either of the unsaturated fatty acid diets, there was no evidence of cerebral IgG immunoreactivity (Fig. 1).
Three-dimensional (3-D) immunodetection of cerebral IgG and apo B extravasation. Perivascular leakage of plasma IgG and apo B into the brain was captured in 3-D utilising highly sensitive immunofluorescent microscopy techniques. IgG is shown in green and apo B is in red. 6-Diamidino-2-phenylindole (DAPI)-counterstained nuclei are shown in blue. (A) Representative 3-D images of plasma IgG and apo B leakage observed in mice fed a SFA-rich diet for 6 months. Scales of x (red), y (red) and z (green) axes are 90 × 80 × 10 μm. (B) Low magnification images of cerebral IgG and apo B immunoreactivity. Significant cerebral extravasation of IgG and apo B was seen in both 3 and 6 month SFA groups. The scale bar indicates 100 μm.
Three-dimensional (3-D) semi-quantitative analysis of cerebral IgG (A and B) and apo B (C and D) extravasation in mice fed a control diet (□), a SFA-rich diet (■), a MUFA-rich diet (
) or a PUFA-rich diet (
) for 3 months (A and C) or 6 months (B and D). The extent of cerebral IgG and apo B abundance was determined in 3-D based on the optical pixel density. Optical pixel densities were measured in three major brain regions of the cortex (CTX), hippocampal formation (HPF) and brain stem (BS) and expressed as per volume unit. Values are means, with standard errors represented by vertical bars. a,b Mean values, within a region, with unlike letters were significantly different (P < 0·05; one-way ANOVA).
Apo B was used as a marker of intestinal and hepatically derived lipoprotein influx into the brain. Native apo B lipoproteins are large macromolecules of 3–50 million kDa molecular weight and a diameter of>23 nm. In SFA-fed mice, apo B immunoreactivity was visible within the CTX and BS at 3 months following commencement of the diet (Fig. 1). However, ingestion of SFA for 6 months exacerbated apo B extravasation and apo B became more evident within the HPF. Analogous to the findings for IgG, mice maintained on the MUFA-enriched, PUFA-enriched or control diet showed no apo B cerebral immunoreactivity at either 3 or 6 months of feeding (Figs. 1 and 2).
Evidence consistent with the possibility that SFA feeding leads to peripheral delivery to the brain of apo B lipoprotein-associated Aβ is shown in Fig. 3. Perivascular distribution of Aβ is clearly seen coinciding with the distribution of apo B lipoproteins (Manders' correlation coefficient 0·843 (sem 0·01); P < 0·0001).
Co-localisation of amyloid-β (Aβ) with perivascualr apo B influx in SFA-fed mice. Significant immunoreactivity of Aβ was detected concomitant with perivascular leakage of apo B lipoproteins in SFA-fed mice, consistent with blood-to-brain delivery of lipoprotein–Aβ. The immunofluorescent images were captured in three dimensions (x, y, z = 70 × 60 × 11 μm), and separated single images of apo B (magenta) and Aβ (yellow), and the merged image are shown. The number of co-localising pixels of different fluorescent dyes was measured by AxioVision software™ (Carl Zeiss, Jena, Germany) utilising Manders' correlation analysis (coefficient = 0·843 (sem 0·01); n 695).
To explore if the pattern of cerebral apo B/Aβ distribution in SFA mice could be relevant to AD aetiology, we also investigated IgG and apo B distribution in 12-month-old APP/PS1 transgenic animals. As found in SFA wild-type mice, the APP/PS1 mice have significant cerebral IgG and apo B extravasation primarily within the CTX, but with significant amounts also within the HPF (Figs. 4 and 5). In addition, utilising highly sensitive 3-D immunodetection, apo B lipoproteins were clearly visible co-localised with Aβ plaque (Manders' correlation coefficient 0·85 (sem 0·004); P < 0·0001; Fig. 6) and plaque abundance positively correlated with apo B immunoreactivity (Pearson's correlation coefficient 0·49 (sem 0·037)).
Three-dimensional (3-D) quantitative immunomicroscopy of cerebral IgG and apo B extravasation in amyloid precursor protein/presenilin-1 (APP/PS1) amyloid transgenic (Tg) mice. The cerebral leakage of plasma IgG and apo B were quantitatively measured by 3-D immunofluorescent detection in the Tg mice. Substantial influx of plasma IgG and apo B into the brain was observed in the Tg mice (white arrows) while no leakages were seen in age-matched wild-type (WT) control mice. Notably, apo B immunoreactivity in the Tg mice strongly co-localised with amyloid plaques (see Fig. 6) while only occasional co-localisation of IgG with plaques was seen (yellow arrow heads). IgG, apo B and nuclei are shown in green, red and blue, respectively. The scale bar indicates 100 μm.
Three-dimensional semi-quantitative analysis of cerebral IgG (A) and apo B (B) extravasation in amyloid precursor protein/presenilin-1 (APP/PS1) amyloid transgenic (Tg; ▨) mice. Optical pixel densities were measured in three major brain regions of the cortex (CTX), hippocampal formation (HPF) and brain stem (BS) and expressed as per volume unit. Values are means, with standard errors represented by vertical bars. * Quantitative analysis based on the pixel density suggested significantly increased immunoreactivity of IgG and apo B in the brain of Tg mice compared with wild-type control mice (
) (P < 0·05; t test).
Co-localisation of apo B with cerebral amyloid plaques. An immunofluorescent double-labelling method was utilised to explore the co-localisation of apo B with amyloid plaques in amyloid precursor protein/presenilin-1 (APP/PS1) transgenic Alzheimer's disease model mice. The distribution of apo B and amyloid-β (Aβ) for the same tissue specimen are shown separately (A and B). The co-location of apo B with Aβ is indicated in the merged image (C). For the latter, Aβ is shown in yellow and apo B is shown in magenta. Scales of x (red), y (blue) and z (green) axes are 70 × 70 × 22 μm.
BBB integrity was also assessed by determining the abundance of occludin (a tight junction protein) relative to vWF. Both in SFA-fed mice and in APP/PS1 transgenic mice, occludin expression was substantially attenuated compared with controls (Figs. 7 and 8). Further evidence that BBB integrity was compromised was suggested by changes in the plasma concentration of S100B (Fig. 9). In the cerebrospinal fluid, S100B level is orders of magnitude greater than in plasma and therefore serves as a useful surrogate marker of brain-to-blood efflux(Reference Kleindienst, Hesse and Bullock32–Reference Yang, Hou and Hamberger33). Mice fed SFA had an 80 % increase in plasma S100B compared with low fat-fed mice, but there was no difference in mice fed either of the unsaturated fatty acid diets (Fig. 9). Similarly, plasma S100B was more than doubled in APP/PS1 mice.
Blood–brain barrier (BBB) three-dimensional (3-D) detection of the tight junction protein occludin. The expression of occludin-1 relative to epithelial cell abundance (expressed as von-Willebrand factor (vWF)) was quantitatively determined using double-labelling immunofluorescent microscopy. Representative 3-D images of occludin and vWF images are shown (x, y, z = 80 × 80 × 7 μm). Significantly decreased expression of BBB occludin was found in SFA-fed mice compared with control mice, consistent with amyloid precursor protein/presenilin-1 (APP/PS1) amyloid trangenic (Tg) mice.
Three-dimensional semi-quantitative analysis of cerebrovascular occludin (A and B) and von-Willebrand factor (vWF) (C and D) in control (□), SFA-fed (■), wild-type () and amyloid precursor protein/presenilin-1 (APP/PS1) amyloid trangenic (▨) mice. Optical pixel intensities were measured in three major brain regions of the cortex (CTX), hippocampal formation (HPF) and brain stem (BS). Immunoreactivities of blood–brain barrier occludin-1 are expressed as per vWF volume unit. The net abundance of vWF is indicated per unit tissue. Values are means, with standard errors represented by vertical bars. * Mean value was significantly different from that of the control mice (P < 0·05; t test). † Mean value was significantly different from that of the wild-type mice (P < 0·05; t test).
Plasma level of S100B. Plasma S100B was determined by ELISA as a surrogate marker of brain-to-blood leakage. Mice fed SFA for 3 months had a significantly higher S100B level compared with the control, MUFA- and PUFA-fed mice. Similarly, amyloid precursor protein/presenilin-1 (APP/PS1) amyloid trangenic (Tg) mice had a doubling in plasma S100B compared with wild-type controls. Values are means, with standard errors represented by vertical bars. a,b Mean values with unlike letters were significantly different (P < 0·01; one-way ANOVA).
The breakdown of the BBB and increased influx of TRL–Aβ in SFA-fed mice did not appear to be a consequence of exaggerated exposure to circulating Aβ, on the basis that the plasma concentration of Aβ1–40 and Aβ1–42 were similar for all groups of wild-type mice (Fig. 10).
Plasma amyloid-β (Aβ) concentration in control and high fatty acid-fed mice. Plasma levels of Aβ1–40 () and Aβ1–42 (
) were measured with ELISA. Values are means, with standard errors represented by horizontal bars. There was no significant difference between the control group and any of the high-fat treatment groups.
Discussion
The present study suggests that chronic ingestion of SFA compromises BBB integrity, resulting in blood-to-brain delivery of plasma proteins, including apo B lipoproteins that may be endogenously enriched in Aβ. Consistent with the notion of BBB dysfunction in SFA-fed mice, there was evidence of cerebrospinal fluid-to-plasma efflux, with a doubling in the plasma concentration of S100B. The detrimental effect of SFA on BBB function seemed to be specific, as no differences were observed between control animals and mice supplemented with either MUFA or PUFA. The cerebral distribution and co-localisation of Aβ with apo B lipoproteins in SFA-fed mice was also found to be remarkably similar to that in APP/PS1 amyloid transgenic mice and in the latter there was a positive association of plasma-derived apo B lipoproteins with cerebral Aβ deposits. The cerebral distribution of apo B and IgG was greater at both 3 and 6 months of SFA feeding within the CTX than the HPF or BS regions, suggesting a site-specific effect. The observation is consistent with the hypothesis of enhanced blood-to-brain delivery of peripheral lipoprotein–Aβ, because the CTX has a more substantial capillary network. Kawai et al. reported that 60–77 % of amyloid plaques were associated with capillaries and relevant to the hypothesis presented in the present study, there was significantly greater vessel density within a 10 μm border surrounding plaques compared with unaffected grey matter(Reference Kawai, Kalaria and Harik34). Collectively, the findings of the present study provide one explanation of how dietary fats may influence AD risk. Ingestion of SFA could enhance peripheral delivery to the brain of circulating lipoprotein–Aβ and exacerbate the amyloidogenic cascade.
The fatty acid-enriched diets provided to mice were well tolerated and there were no significant differences in weight gain, plasma cholesterol or plasma TAG between groups. Therefore changes to BBB integrity in SFA-fed mice were not a consequence of dietary induced dyslipidaemia. The diets were physiologically relevant. Palmitic (16 : 0) and stearic (18 : 0) acid content of the mouse diets of 5·2 and 7·1 % of energy intake, respectively, is comparable with Western patterns of consumption of between 5 and 7 % for each. Total saturates of the mouse chow were also similar to Western dietary patterns (13 % mouse SFA chow v. 14 % in human diets) as well as total digestible energy as lipids (40 % for fatty acid-supplemented chow v. 37 % in Western diets).
We put forward the hypothesis that an SFA-induced elevation in plasma Aβ might compromise BBB function on the basis that exogenous administration of this protein showed disturbing vasoreactive properties in vivo. However, in the present study the plasma concentrations of Aβ1–40 and Aβ1–42 were similar for all groups of wild-type mice. We cannot equivocally rule out an elevation in the lipoprotein pool of Aβ because some studies suggest that lipids block detection of lipoprotein-bound Aβ(Reference Yanagisawa, McLaurin and Michikawa35, Reference James and Mamo36).
The SFA diet may have also compromised BBB function mechanisms independent of lipoprotein–Aβ concentration, including enhanced production of reactive oxygen species, increases in intracellular Ca or activation of endoplasmic reticulum stressors(Reference Morgan37–Reference Solfrizzi, Frisardi and Capurso40). Clinical evidence suggests that inflammatory pathways can become activated because of impaired postprandial lipid metabolism(Reference Van oostrom, Alipour and Plokker41). Important differences in the cytotoxic effects of fatty acids have been reported, with longer-chain SFA being the most potent and the MUFA and PUFA being cytoprotective(Reference Morgan37). Morgan(Reference Morgan37) suggests that the underlying toxicity of SFA is a consequence of disturbances in protein processing and endoplasmic reticulum dysfunction, for example, apoptotic induction. Consistent with this hypothesis, Patil et al. reported a palmitic acid-induced region-specific damage because of a higher fatty acid-metabolising capacity of cortical astroglia(Reference Patil, Balu and Melrose42). Conversely, cell-culture studies suggest that incubation, particularly with longer-chain unsaturates, has an antagonistic effect on endoplasmic reticulum-centred stress pathways(Reference Diakogiannaki and Morgan43).
Dietary ‘lipotoxicity’ refers to the processes leading to end-organ damage and/or dysfunction following excess exposure to fatty acids and was first coined in the context of fat-induced insulin resistance(Reference Unger44). Since then, however, the process has also been implicated in endothelial dysfunction and atherosclerosis, heart failure, kidney failure, steatohepatitis and liver failure, autoimmune inflammatory disorders, susceptibility to infections, cancer and ageing. The BBB disturbances identified in the present study may reflect a broader dietary toxic phenomenon.
SFA may also have compromised BBB function by secondary pathways other than elevations in plasma Aβ, or as a consequence of interactive effects with genes involved in Aβ metabolism and BBB function. For example, Deane et al. showed that apoE isoforms differentially regulate Aβ clearance from the brain by routing free Aβ through alternate receptors at the BBB. Apo E4-facilitated efflux was slower than apo E3- or apo E2-mediated clearance(Reference Deane, Sagare and Hamm45, Reference Deane, Bell and Sagare46). The effect of SFA on apo E isoforms was not explored in the present study.
Apo B immunoreactivity in senile plaque of subjects with AD was reported some years ago(Reference Namba, Tsuchiya and Ikeda47) but there was no evidence that this association was causal. However, several lines of study are consistent with the concept that peripheral delivery of lipoprotein–Aβ may contribute to AD risk(Reference Refolo, Malester and LaFrancois5, Reference Takechi, Galloway and Pallebage-Gamarallage18, Reference Cole and Ard48–Reference Takechi, Galloway and Pallebage-Gamarallage50). Firstly, Aβ is tightly bound to TRL, the secretion of which is positively associated with the onset and progression of cerebrovascular and parenchymal amyloidosis(Reference James, Pal and Gennat20–Reference Mamo, Jian and James21). Indirect evidence for the possibility of enhanced lipoprotein-mediated blood-to-brain delivery of Aβ is suggested by the study of Kreuter et al. who demonstrated enhanced drug transport into the brain when nanoparticles were covalently attached to apolipoproteins (including apo B)(Reference Kreuter, Hekmatara and Dreis51). In clinical studies significantly greater levels of apo B are found in AD patients(Reference Caramelli, Nitrini and Maranhao52) and indirect evidence also comes from studies investigating the pro-atherogenic properties of apo B lipoproteins, a disease that shares some pathological similarities to AD. In arterial tissue, apo B lipoproteins and particularly the post-hydrolysed remnants of apo B lipoproteins have significant affinity for extracellular matrices and, if trapped, induce an inflammatory response(Reference Mamo, Proctor and Smith53). The uptake by resident macrophages of apo B lipoproteins triggers a respiratory burst compromising cell viability leading to atherosclerotic plaque instability(Reference Elsegood, Pal and Roach54). Obesity and diabetes also significantly increase risk for AD(Reference Profenno, Porsteinsson and Faraone55). Profenno et al. (Reference Profenno, Porsteinsson and Faraone55) suggested that physiological changes common to obesity and diabetes plausibly promote AD. Resistance to the action of insulin in obese/diabetic individuals results in hepatic and intestinal apo B lipoprotein overproduction, diminished clearance of apo B lipoproteins from blood and postprandial dyslipidaemia(Reference Mamo, Watts and Barrett56). It is possible that the cerebral parenchymal entrapment of lipoprotein–Aβ and formation of fibrillar deposits share pathways in common with the initiation of progression of atherosclerosis.
Nelson & Alkon(Reference Nelson and Alkon57) suggested that fibrillar formation of Aβ is prevented by proteins such as apo B that have affinity for the Aβ hydrophobic domain. Using a phage display system to explore protein–protein interaction, they found that Aβ binds to proteins primarily involved in LDL and cholesterol transport. However, given that apo B is a protein not normally found in cerebrospinal fluid it is unlikely to serve as a suppressor of amyloidosis. Rather, cerebrovascular remodelling of apo B lipoprotein–Aβ delivered to the brain could exacerbate amyloidogenesis as a result of Aβ release, or enhanced epitope exposure(Reference Kay, Day and Nicoll30).
There is an accumulating body of literature consistent with the concept that the onset and progression of AD is influenced by lifestyle factors including nutrition. Population studies support a role of dietary fats in AD. Laitinen et al. reported that intake of unsaturated fats is protective, whereas intake of saturates increases risk of AD(Reference Laitinen, Ngandu and Rovio58). In the Framingham study, the top quartile of plasma DHA was associated with a 47 % reduction in risk of all-cause dementia(Reference Schaefer, Bongard and Beiser59). Furthermore, evidence continues to come from animal studies including by Oksman et al. who confirmed that saturates increase, while DHA decreases, cerebral Aβ levels compared with a soya oil diet(Reference Oksman, Iivonen and Hogyes60).
The present study provides novel insight into how dietary fats might influence AD risk and reports for the first time differential effects of dietary fatty acids on BBB integrity. Mice chronically fed SFA show significant blood-to-brain delivery, retention and accumulation of apo B lipoproteins, primarily within the CTX of SFA-fed mice, observations consistent with the distribution of apo B in amyloid in brain specimens from subjects with AD. In the present study, chronic ingestion of SFA in wild-type mice also replicated the pattern of BBB dysfunction and of TRL–Aβ distribution observed in an established model of AD (APP/PS1 transgenics) maintained on normal chow. How dietary behaviour influences BBB function and the propensity for amyloidosis may prove helpful in the context of AD prevention.
Acknowledgements
The present study was financially supported by the National Health and Medical Research Council of Australia, and the Australian Technology Network Centre for Metabolic Fitness.
R. T. conducted the experimental procedures and prepared the manuscript. S. G. contributed to the animal care and experimental data collection. M. M. S. P.-G. contributed to experimental data collection. C. L. W. contributed to animal sample preparation. R. D. J. contributed to the development of methods. S. S. D. contributed to the experimental design and statistical assessment. J. C. L. M. contributed to the project concept, research funding, experimental design, data collection and writing of the manuscript.
The authors declare no conflicts of interest.
